Showing 1351-1360 of 1560 results for "".
- Melt Pharmaceuticals Announces Development and License Agreement with Catalent for Its Zydis Fast-Dissolve Technologyhttps://modernod.com/news/melt-pharmaceuticals-announces-development-and-license-agreement-with-catalent-for-its-zydis-fast-dissolve-technology/2481857/Melt Pharmaceuticals, a former subsidiary of Harrow Health, announced it has entered into an exclusive development and license agreement with Catalent in which Melt will utilize Catalent’s proprietary Zydis orally disintegrating tablet (ODT) fast-dissolve technology with MELT
- Erin Powers Joins J&J Vision as Vice President of US Sales and Marketing for its Surgical Vision Portfoliohttps://modernod.com/news/erin-powers-joins-jj-vision-as-vice-president-of-us-sales-and-marketing-for-its-surgical-vision-portfolio/2481838/Johnson & Johnson announced the appointment of Erin Powers to the position of Vice President of US Sales and Marketing for its Surgical Vision portfolio. Ms. Powers will lead the US sales, marketing, and professional education teams, and will join the company within t
- Business Executive Alex Gorsky Joins Neurotech’s Board as Lead Directorhttps://modernod.com/news/business-executive-alex-gorsky-joins-neurotechs-board-as-lead-director/2481827/Neurotech Pharmaceuticals announced that Alex Gorsky has been elected to Neurotech’s board as Lead Director. Mr. Gorsky is the former Chairman and CEO of Johnson & Johnson. Under Mr. Gorsky’s leadership, Johnson & Johnson grew to become one of world’s larg
- CXL Ophthalmics Appoints Tiffany Haynes as Vice President of Clinical Operationshttps://modernod.com/news/cxl-ophthalmics-appoints-tiffany-haynes-as-vice-president-of-clinical-operations/2481468/CXL Ophthalmics announced that Tiffany Haynes has been appointed as Vice President of Clinical Operations. With more than 25 years of experience in ophthalmology, Ms. Haynes previously served as Global Director, Medical Affairs for Johnson & Johnson Vision. There, she was respo
- J&J Vision Receives CE Mark Approval for the ELITA Femtosecond Laser Systemhttps://modernod.com/news/jj-vision-receives-ce-mark-approval-for-the-elita-femtosecond-laser-system/2481440/Johnson & Johnson Vision has received CE Mark approval for the ELITA Femtosecond Laser System for laser vision correction. The new laser will allow surgeons to perform refractive correction on patients with myopia, with or without astigmatism, via a new lenticular procedure called t
- J&J Vision Presents New Data on Myopia, IOLs, Phacoemulsification, Dry Eye Drops, Vision Science and Refractive Technologieshttps://modernod.com/news/jj-vision-presents-new-data-on-myopia-iols-phacoemulsification-dry-eye-drops-vision-science-and-refractive-technologies-at-arvo/2480839/Johnson & Johnson Vision is presenting 26 poster and podium presentations focusing on myopia, cataract, dry eye, vision science, and refractive research at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Live and Virtual Annual Meeting. Johnson & Johnson Vision poster
- J&J Vision Presents Data Validating Improved Surgical Outcomes and Surgeon Satisfaction at ASCRShttps://modernod.com/news/johnson-johnson-vision-presents-data-validating-improved-surgical-outcomes-and-surgeon-satisfaction-across-cataract-and-refractive-portfolio-at-ascrs/2480787/Johnson & Johnson Vision will present and/or support 46 company-sponsored and investigator-led studies evaluating innovations and outcomes across its surgical portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Washington, DC, April 22-26.
- Neurophth Therapeutics' Treatment of Leber's Hereditary Optic Neuropathy Gene Therapy NR082 Granted Orphan Drug Designation by EMAhttps://modernod.com/news/neurophth-therapeutics-treatment-of-lebers-hereditary-optic-neuropathy-gene-therapy-nr082-granted-orphan-drug-designation-by-ema/2480605/Neurophth Therapeutics announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) granted the orphan drug designation (ODD) for the company's leading gene therapy drug candidate, NR082 (rAAV2-ND4), for the treatment of Leber's hereditary opt
- MeiraGTx Receives Clinical Development Milestone Payment from Janssenhttps://modernod.com/news/meiragtx-receives-clinical-development-milestone-payment-from-janssen/2480599/MeiraGTx Holdings announced that it has received a $30 million payment from Johnson & Johnson's Janssen Pharmaceuticals for a clinical milestone in the phase 3 Lumeos trial of botaretigene sparoparvovec (AAV-RPGR), an investigational gene therapy for the treatment of X-linked retinit
- Mitotech Granted Orphan Drug Designation by FDA for Visomitin in LHONhttps://modernod.com/news/mitotech-granted-orphan-drug-designation-by-fda-for-visomitin-in-lhon/2480520/Luxembourg-based Mitotech SA announced that the FDA has granted orphan drug designation (ODD) for the company’s topical cardiolipin peroxidation inhibitor, Visomitin, for the treatment of Leber’s Hereditary Optic Neuropathy (LHON), a rare inherited condition that can lead to blin